SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines. Learn more.
Ultrasound-mediated delivery of non-viral gene therapy vector expressing COL4a5 in X-Linked Alport Syndrome (XLAS) disease model mice and non-human primates